


AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph at page 4, lines 9-18 with the following amended

paragraph:

Preferably the radical initiator is of the general formula V



where:

Y^1 is selected from the group consisting of Cl, Br, I, OR¹⁰, SR¹⁴, SeR¹⁴, OP(=O)R¹⁴, OP(=O)(OR¹⁴)₂, O-N(R¹⁴)₂ and S-C(=S)N(R¹⁴)₂, where R¹⁰ is alkyl of from 1 to 20 carbon atoms in which each of the hydrogen atoms may be independently replaced by halide, R¹⁴ is aryl or a straight or branched C₁-C₂₀ alkyl group, and where an N(R¹⁴)₂ group is present, the two R¹⁴ groups may be joined to form a 5- or 6-membered heterocyclic ring;

Please replace the paragraph at page 4, lines 19-26 with the following amended

paragraph:

R¹¹ and R¹² are each independently selected from the group consisting of H, halogen, C₁-C₂₀ alkyl, C₃-C₈ cycloalkyl, C(=O)R¹⁵, C(=O)NR¹⁶R¹⁷, COCl, OH, CN, C₂-C₂₀ alkenyl, oxiranyl, glycidyl, aryl, heterocyclyl, aralkyl and aralkenyl, in any of which the alkyl, alkenyl or aryl, heterocyclyl or cycloalkyl groups there may be from 1 to 3 substituents selected from the group consisting of hydrogen, hydroxy C₁-C₄ alkoxy, acyloxy, aryl, heterocyclyl, C(=O)R¹⁵, C(=O)NR¹⁶R¹⁷, $\text{-CR}^{12}\text{R}^{13}\text{Y-}\text{CR}^{12}\text{R}^{13}\text{Y}^1$, $\text{CR}^{11}\text{R}^{12}\text{Y}^1\text{CR}^{11}\text{R}^{12}\text{Y}$, oxiranyl and glycidyl;

Please replace the paragraph at page 5, lines 8-16 with the following amended

paragraph:

R^{13} is selected from the group consisting of biologically active group-substituted alkyl, cycloalkyl, $-\text{COR}^{15}$, $-\text{CONR}^{16}\text{R}^{17}$, alkenyl, aryl, heterocyclyl, aralkyl and aralkenyl groups, in any of which the alkyl, alkenyl, aryl, heterocyclyl or cycloalkyl groups may have from 1 to 3 substituents selected from the group consisting of hydrogen, hydroxy, $\text{C}_1\text{-C}_4$ alkoxy, acyloxy, aryl, heterocyclyl, $\text{C}(=\text{O})\text{R}^{15}$, $\text{C}(=\text{O})\text{NR}^{16}\text{R}^{17}$, $-\text{CR}^{12}\text{R}^{13}\text{Y}^1$, $-\text{CR}^{12}\text{R}^{13}\text{Y}$, $\text{CR}^{14}\text{R}^{12}\text{Y}$, $\text{CR}^{11}\text{R}^{12}\text{Y}^1$, oxiranyl and glycidyl where R^{15} , R^{16} and R^{17} are groups as defined above for R^{11} and R^{12} with the biologically active group substituted on an alkyl, cycloalkyl, alkenyl, aryl or heterocyclyl group.

Please replace the paragraph at page 5, lines 23-25 with the following amended

paragraph:

Since any of R^{11} , R^{12} and R^{13} may comprise a substituent $\text{CR}^{12}\text{R}^{13}$ or $-\text{CR}^{14}\text{R}^{12}\text{Y}$, $\text{CR}^{11}\text{R}^{12}\text{Y}^1$, the initiator may be di-, oligo- or poly- functional. Preferably it is a mono-functional initiator.